PT-141 (Bremelanotide)

Product Overview

PT-141 was developed by Palatin Technologies and approved by the FDA as a first-in-class medication for HSDD in premenopausal women. It is a synthetic peptide analog of alpha-MSH that targets the root neurological cause of low libido rather than peripheral vascular mechanisms. It is administered via subcutaneous injection at least 45 minutes before anticipated sexual activity, with a maximum of 8 doses per month.

Mechanism of Action

PT-141 acts as an agonist at melanocortin receptors (MC1R > MC4R > MC3R > MC5R > MC2R). MC4R receptors in the hypothalamus are involved in sexual behavior. PT-141 stimulates dopamine production in the medial preoptic area, a brain region central to sexual desire and arousal. This central mechanism provides a fundamentally different approach from PDE5 inhibitors.

Key Benefits

Central Nervous System Targeting — Acts directly on hypothalamic neurons to stimulate natural dopamine-mediated sexual desire and arousal, addressing the root cause of low libido.

Rapid Onset — Effects typically observed within 30–45 minutes of subcutaneous administration, faster than many oral ED medications.

Gender-Inclusive Efficacy — FDA-approved for women (HSDD) and studied for men. Enhances libido and arousal in both sexes through central melanocortin activation.

Favorable Tolerability — Clinical trials report mild and transient side effects (flushing, nausea). Does not cause dependency or hormonal disruption.

References

1. Kingsberg SA, et al. The female sexual response: current models and agents under investigation for HSDD. *CNS Drugs.* 2015;29(11):915–933.
2. Miller MK, et al. Expert opinion on existing and developing drugs to treat female sexual dysfunction. *Expert Opin Emerg Drugs.* 2018;23(3):223–230.
3. Bremelanotide Acetate Monograph for Professionals. *Drugs.com.* 2019.